Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) - Bridging the River Coumarin

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 2-3

  Warkentin, Theodore E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; WARFARIN;

ANTICOAGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; EDITORIAL; ENZYME IMMUNOASSAY; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG DISEASE; NECROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REBOUND; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE COUNT;

ACUTE DISEASE; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PIPECOLIC ACIDS; PLATELET COUNT; POLYSACCHARIDES; RECOMBINANT PROTEINS; RESEARCH DESIGN; THROMBIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 38349135867     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-12-0713     Document Type: Editorial

References (10)

1. Bradner JE, Eikelboom JW. Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inbibitors. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 4th ed. New York: Informa Healthcare USA, Inc.; 2007: 441-461.
2. Warkentin TE, Cook RJ, Marder VJ, et al.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
3. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
4. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Pharmacotherapy 2006; 40: 1383-1387.
5. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71: 50-52.
6. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumatin? J Thromb Haemost 2006; 4: 894-896.
7. Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
8. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94: 958-964.
9. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82: 1037-1043.
10. Lubenow N, Warkentin TE, Greinacher A, et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117: 507-515.